Dr. Michal Bar-Natan, MD
Claim this profileIcahn School of Medicine at Mount Sinai
Studies Acute Myeloid Leukemia
Studies Lymphoma
5 reported clinical trials
21 drugs studied
Area of expertise
1Acute Myeloid Leukemia
BCR-ABL1 positive
CD19 positive
PML-RARA negative
2Lymphoma
BCR-ABL1 positive
CD19 positive
CRLF2 positive
Affiliated Hospitals
Clinical Trials Michal Bar-Natan, MD is currently running
ABL001 Combo Therapy
for Leukemia
This research study is evaluating a drug called ABL001 taken in combination with dasatinib (Sprycel®) and prednisone (a steroid) as a possible treatment for B-cell Acute Lymphoblastic Leukemia that is BCR-ABL positive (BCR-ABL+ B-ALL) or Chronic Myeloid Leukemia (CML) in lymphoid blast crisis. BCR-ABL+ B-ALL is also called Philadelphia chromosome positive Acute Lymphoblastic Leukemia (Ph+ ALL). It is expected that 25-40 people will take part in this research study. * ABL001 * Dasatinib (Sprycel®) * Prednisone * Blinatumomab
Recruiting1 award Phase 1
Peptide-based Vaccine
for Myeloproliferative Disorders
The primary objective of this study is to assess the safety and tolerability of administrating mutated-CALR peptide Vaccine to patients with MPN. The researchers plan to enroll 10 patients over a 12 month period. Maximum length of participation in 80 weeks. Patients will be asked to complete questionnaires, bone marrow biopsies, research lab collection, and standard of care lab draw. This research will be taking place only at The Mount Sinai Hospital, specifically at the Ruttenberg Treatment Center.
Recruiting1 award Phase 1
More about Michal Bar-Natan, MD
Clinical Trial Related5 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Michal Bar-Natan, MD has experience with
- Cytarabine
- Dasatinib
- Prednisone
- ABL001
- Mutant CALR-peptide Based Vaccine
- Inotuzumab Ozogamicin
Breakdown of trials Michal Bar-Natan, MD has run
Acute Myeloid Leukemia
Lymphoma
Acute Lymphoblastic Leukemia
Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michal Bar-Natan, MD specialize in?
Michal Bar-Natan, MD focuses on Acute Myeloid Leukemia and Lymphoma. In particular, much of their work with Acute Myeloid Leukemia has involved BCR-ABL1 positive patients, or patients who are CD19 positive.
Is Michal Bar-Natan, MD currently recruiting for clinical trials?
Yes, Michal Bar-Natan, MD is currently recruiting for 2 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Michal Bar-Natan, MD has studied deeply?
Yes, Michal Bar-Natan, MD has studied treatments such as Cytarabine, Dasatinib, Prednisone.
What is the best way to schedule an appointment with Michal Bar-Natan, MD?
Apply for one of the trials that Michal Bar-Natan, MD is conducting.
What is the office address of Michal Bar-Natan, MD?
The office of Michal Bar-Natan, MD is located at: Icahn School of Medicine at Mount Sinai, New York, New York 10029 United States. This is the address for their practice at the Icahn School of Medicine at Mount Sinai.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.